Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene and protection. The company was incorporated in 2020 and is based in Mumbai, India.

Revenue projections:

Revenue projections for PPLPHARMA
Revenue projections for PPLPHARMA

Piramal Pharma Limited is projected to experience a revenue decline compared to last year, a development that often leads to investor caution. The drop could negatively impact the company's bottom line, as lower revenues typically signal reduced profitability, prompting more conservative investment strategies.

Financial Ratios:

currentRatio 0.00000
forwardPE 42.33859
debtToEquity 59.76800
earningsGrowth 0.00000
revenueGrowth -0.00900
grossMargins 0.60862
operatingMargins -0.04684
trailingEps 0.74000
forwardEps 0.00000

PPLPHARMA's low growth in earnings and revenue indicates that profits could shrink. This signals potential financial difficulties for the company, suggesting that its profitability might be under pressure.

Price projections:

Price projections for PPLPHARMA
Price projections for PPLPHARMA

Price projections for Piramal Pharma Limited have been gradually reduced, reflecting growing uncertainty about the company's future performance. The downward revisions indicate analysts are lowering their expectations for Piramal Pharma Limited's market trajectory.

Recommendation changes over time:

Recommendations trend for PPLPHARMA
Recommendations trend for PPLPHARMA


With analysts showing a buy bias for PPLPHARMA, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning PPLPHARMA as a safe and profitable place for investors to allocate their funds and seek growth.